




The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 61% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 5.6% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	134,208
Cost of Goods Sold	15,277
Intangible Assets	16,836
Liabilities, Current	48,834
Liabilities, Non-Current	6,305
Other Assets	12,739
Other Compr. Net Income	-1,413
Other Expenses	10,583
Other Liabilities	35,249
Other Net Income	4,150
Other Revenues	169,117
Property and Equipment	453
Research and Development	15,196
Selling, General and Administrative Expense	181,043

Output Variable	Value in 1000 USD
Assets	164,236
Liabilities	90,388
Expenses	222,099
Revenues	169,117
Stockholders Equity	73,848
Net Income	-48,832
Comprehensive Net Income	-49,538
BaseVar	325,702
ECR before LimitedLiability	88%
Economic Capital Ratio	220%